Anthem Biosciences: The unaudited standalone and consolidated financial results for the period ended September 30, 2026
Anthem Biosciences (ANTHEM) filed a disclosure titled "The unaudited standalone and consolidated financial results for the period ended September 30, 2026". The company is valued at about ₹47,071 crore.
What happened
Anthem Biosciences (ANTHEM) filed a disclosure with the exchanges on 3 November 2026 at 05:53 PM titled "The unaudited standalone and consolidated financial results for the period ended September 30, 2026".
From the filing: "Anthem Biosciences Limited has submitted to the Exchange, the unaudited standalone and consolidated financial results for the period ended September 30, 2026."
Company snapshot
Anthem Biosciences is a mid-cap company in the Healthcare sector, with a market value of about ₹47,071 crore.
The stock last traded at ₹835.5, against a 52-week range of ₹579.2–₹977.6 (14.5% below the high).
Before this filing the shares had moved −2.7% over the month and +0.7% over three months. Average daily turnover over the last 20 sessions was about ₹30.2 crore.
Promoters held 71.42% at the end of Q1 FY27, down 3.26% points from the previous quarter. Foreign institutions owned 2.58% and domestic institutions 13.48%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 540 | 135.8 | 2.43 |
| Q2 FY26 | 550 | 173.4 | 3.09 |
| Q3 FY26 | 423 | 92.8 | 1.65 |
| Q4 FY26 | 611 | 189.8 | 0 |
| Q1 FY27 | 418 | 119.9 | 2.13 |
What history shows
BCEIE's records show 3 previous results filings from the company since May 2026.
After those filings, the stock fell 1.7% on average the next trading day and was down 0.2% on average after five days (2 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +1.9% over five days; 57% of them rose the next day.
Market-wide, 10,321 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 21 Jul 2026 | A press release dated July 21, 2026, titled "Press Release on the… | −1.7% | −0.2% |
| 21 Jul 2026 | , the financial results for the period ended Jun 30, 2026. | −1.7% | −0.2% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 3 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.